



Melanoma Bridge 2016

Preliminary Program

Royal Continental Hotel, Naples
November 30th –December 3rd, 2016

*Speakers to be confirmed are indicated with**

*Not included in the CME accredited program are indicated with***

November 30th

17.30 – 18.15 Registration

18.15 – 18.30 Welcome and Introduction**

18.30 – 19.00 Opening lecture of Melanoma Bridge**, Alexander Eggermont*

19.00 – 19.30 Welcome Cocktail

December 1st

09.00 – 09.30 Registration

Session I –Evolving Topics in Cancer Immunotherapy

Coordinators: Paolo A. Ascierto, Sandra Demaria, Giuseppe Masucci, Magdalena Thurin

09.30 - 09.50 Treatment--induced molecular pathways regulate the immunogenicity of radiotherapy, Sandra Demaria

09.50 - 10.10 In situ tumor vaccination using local radiotherapy and intratumoral immunocytokine, Paul Sondel

10.10 - 10.30 (Cancer vaccines), Cornelis J.M. Melief

10.30 - 10.50 Therapy of solid cancers using T cells and running shoes, Per thor Straten

10.50 - 11.05 Break**

11.05 - 12.05 Discussion on the best research studies on Evolving Topics in Cancer Immunotherapy **

Symposium: "Evolving Topics in Cancer Immunotherapy: Combination"

12.05 – 12.25 How combination is changing the immunotherapy scenario, Paolo A. Ascierto

12.25 – 12.45 New ways of thinking about the ipilimumab + nivolumab combination regimen, Michael Postow

12.45 – 13.05 Discussion, Paolo A. Ascierto



13.05 - 13.20 Conclusions, Paolo A. Ascierto, Sandra Demaria, Giuseppe Masucci, Magdalena Thurin

13.20 - 14.20 Lunch**

Symposium: "Merkel Cell Carcinoma and Cancer Immunotherapy"

14.20 – 14.40 Immune checkpoint blockade and cancer therapies, Paolo A. Ascierto

14.40 – 15.00 New treatment approaches in merkel cell carcinoma, Celeste Lebbe

15.00 – 15.20 Discussion, Paolo. A. Ascierto

Session II - World-Wide Immunoscore Task Force

Chairpersons: Paolo A. Ascierto, Jerome Galon, Francesco M. Marincola

15.20 - 15.40 Immunoscore worldwide consortium and beyond, Jerome Galon

15.40 – 16.00 Immunoprofiling in melanoma, Paolo A. Ascierto

16.00 - 16.20 Implementation of the Immunoscore in a Pathology Lab based on the LEAN Management System, Alessandro Lugli

16.20 - 16.35 Break**

16.35 - 16.55 Suppressive Index: the other side of the Immunoscore? Carlo Bifulco

16.55 - 17.15 The immunoscore beyond cancer, Franck Pages

17.15 - 17.35 Immunoscore and other prognostic factors in the personalized cancer treatment's scenario, Giuseppe Masucci

17.35 - 17.55 Discussion

17.55 - 18.30 Conclusions, Paolo A. Ascierto, Jerome Galon, Francesco M. Marincola

December 2nd

Session III - System biology Session: Molecular

Chairpersons: Luigi Buonaguro, Ena Wang

09.30 - 09.50 microRNAs regulate resistance to target therapy in melanoma, Gennaro Ciliberto

09.50 - 10.10 Melanoma Mutations and Precision Medicine, Ruth Halaban

10.10 - 10.30 Resistance to MAPK and checkpoint targeted therapy, Roger Lo

10.30 - 10.50 Biomarkers for treatment decision? Reinhard Dummer

10.50 - 11.05 Break

11.05 - 12.05 Discussion on the best research studies on System biology Session: Molecular **

Symposium: Bringing overall survival in BRAF + MM Patients: the combined inhibition of Braf & Mek
 12.05 – 12.25 Mode of action of BRAF/MEK inhibitors, Paolo A. Ascierto
 12.25 – 12.45 Transforming melanoma from an acute to chronic disease: examining new evidences on BRAF and MEK inhibitors, Reinhard Dummer
 12.45 – 13.05 Discussion

13.05 - 13.20 Conclusions, Luigi Buonaguro, Ena Wang

13.20 - 14.20 *Lunch***

Session IV - Combination Strategy Session

Chairpersons: Nicola Mozzillo, Giuseppe Palmieri

Symposium: Raising the bar: combining evidence and practice to improve outcomes in BRAF mutated metastatic melanoma patients**

14.20 – 14.40 Latest evidences on the combination vemurafenib-cobimetinib in BRAF mutated metastatic melanoma**, Paolo A. Ascierto
 14.40 – 15.00 Optimal management of BRAF mutated patients treated with vemurafenib-cobimetinib:
 Case 1) vemurafenib-cobimetinib in a normal LDH patient
 Case 2) vemurafenib-cobimetinib in a young patient **
 Karl Lewis
 15.00 – 15.20 Discussion

Sponsored by ROCHE

15.20 - 15.40 Overcoming radiation-induced barriers to an immune response, Silvia C. Formenti

15.40 – 16.00 Where are we really with clinical trials of combination immunotherapy? Michael Postow

16.00 - 16.20 Combining checkpoint and targeted inhibitors, Igor Puzanov

16.20 - 16.40 Innovative combination strategies – oncolytic therapy and systemic immunotherapy approaches, Sanjiv Agarwala

16.40 - 16.55 *Break***

16.55 - 17.55 Discussion on the best research studies on Combination Strategy**

17.55- 18.30 Conclusions, Nicola Mozzillo, Giuseppe Palmieri

December 3rd

Session V - System biology Session: Immunology

Chairpersons: Alexander Eggermont *, Giuseppe Masucci

09.10 – 09.30 Rational Design of Combination Immunotherapy, Samir Khleif

09.30 - 09.50 Bioinformatic approaches to investigate mechanisms driving the non-T cell-inflamed tumor microenvironment, Jason Luke

09.50 - 10.10 Gut microbiome bridging systemic and anticancer immunity, Laurence Zitvogel



- 10.10 - 10.30 Next Targets for Immune Checkpoint Blockade, Hassane Zarour
- 10.30 - 10.50 Advances in Dendritic Cell Cancer Immunotherapy, David Stroncek
- 10.50 - 11.05 *Break***
- 11.05 - 12.05 Discussion on the best research studies on System biology Session: Immunology **

Symposium: "Immuno-oncology: a revolution in the treatment strategy of advanced melanoma"***

- 12.05 - 12.25 TBD, Paolo A. Ascierto
- 12.25 - 12.45 TBD, Sanjiv Agarwala
- 12.45 - 13.05 Discussion

Sponsored by MSD

- 13.05 - 13.20 Conclusions, Alexander Eggermont*, Giuseppe Masucci

13.20 - 14.20 *Lunch***

Session VI - Biomarkers Session

Chairpersons: Gerardo Botti*, Alessandro Testori

- 14.20 - 15.00 The promising alliance of electrochemotherapy and immunotherapy, Lluís Mir
- 15.00 - 15.20 CSPG4 as a target of antibody-based immunotherapy, Soldano Ferrone
- 15.20 - 15.40 Prognostic and predictive markers for patients treated with CTLA-4 and PD-1 inhibitors, Claus Garbe
- 15.40 - 16.00 Update on PD-L1 and related markers, Janis M. Taube
- 16.00 - 16.15 *Break*
- 16.15 - 16.35 Understanding mechanisms of response and resistance to melanoma therapy: lessons learned from mouse and man, Jennifer Wargo
- 16.35- 17.35 Discussion on the best research studies on Biomarkers Session **
- 17.35 - 18.10 Conclusions, Gerardo Botti*, Alessandro Testori



Presidency

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Nicola Mozzillo

Director of the Department of Surgical Oncology B, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Scientific Board

Sanjiv Agarwala

Chief of Medical oncology and Hematology, St. Luke's University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Gennaro Ciliberto

Scientific Director, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Reinhard Dummer

Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich

Bernard A. Fox

Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Claus Garbe

University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci

Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Nicola Mozzillo

Director of the Department of Surgical Oncology B, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Michael Postow

Memorial Sloan Kettering Cancer Center, New York



Igor Puzanov

Professor of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Ena Wang

Division Chief of Translational Medicine, Sidra Medical and Research Centre, Doha, Qatar

Tara Withington

Executive Director, Society for Immunotherapy of Cancer, Milwaukee

Faculty

Sanjiv Agarwala

St. Luke's University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Carlo Bifulco

Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Gerardo Botti

National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Luigi Buonaguro

National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Gennaro Ciliberto

National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Sandra Demaria

New York University School of Medicine and NYU Langone Medical Center Alexandria Center for Life Sciences, New York

Reinhard Dummer

University of Zurich Hospital, Department of Dermatology, Zurich

Alexander Eggermont

Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

Soldano Ferrone

Massachusetts General Hospital, Boston, Massachusetts

Silvia C. Formenti

Department of Radiation Oncology, Weill Cornell Medical College, New York



Jerome Galon

INSERM (National Institute of Health and Medical Research), Paris, France

Claus Garbe

Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Ruth Halaban

Department of Dermatology, Yale University School of Medicine, New Haven

Samir Khleif

Georgia Cancer Center, Augusta University, Augusta, Georgia

Roger Lo

Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California

Alessandro Lugli

Institute of Pathology, University of Bern, Switzerland

Francesco M. Marincola

Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Cornelis J.M. Melief

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.

Lluis Mir

Gustave Roussy, Paris, France

Nicola Mozzillo

National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Franck Pages

Service d'Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France

Giuseppe Palmieri

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Michael Postow

Memorial Sloan Kettering Cancer Center, New York

Igor Puzanov

Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee

Paul Sondel

University of Wisconsin School of Medicine and Public Health, Milwaukee

David Frank Stroncek



Cell Processing Section Department of Transfusion Medicine Clinical Center, National Institutes of Health Center, Bethesda, Maryland

Janis M. Taube

Johns Hopkins University SOM, Baltimore, Maryland

Alessandro Testori

Dermato-oncology Surgery Division, European Institute of Oncology, Milan, Italy

Per thor Straten

Department of Immunology and Microbiology, University of Copenhagen, Denmark

Magdalena Thurin

Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Ena Wang

Sidra Medical and Research Centre, Doha, Qatar

Jennifer A. Wargo

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Hassane Zarour

University of Pittsburgh Cancer Institute Hillman Cancer Center, Pennsylvania

Laurence Zitvogel

Institut Gustave Roussy, Villejuif, Paris-Sud, France